Triple-Drug attack shows promise for tough colorectal cancer
NCT ID NCT04017650
First seen Nov 19, 2025 · Last updated Jun 18, 2026 · Updated 34 times
Summary
This study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy (nivolumab) in people with a specific type of advanced colorectal cancer (BRAF V600E mutation) that is stable (MSS) and has spread or can't be removed by surgery. The goal is to see if this triple therapy can shrink tumors better than standard treatment. About 38 adults with this hard-to-treat cancer are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III COLORECTAL CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.